GnT-II CRISPR/Cas9 KO Plasmid (h): sc-407393
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GnT-II CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GnT-II genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GnT-II CRISPR/Cas9 KO Plasmid (h) | sc-407393 | 20 µg | $397.00 |
Overview
MGAT2 encodes N-acetylglucosaminyltransferase II (GnT-II), a medial-Golgi glycosyltransferase that catalyzes a key step in the synthesis of complex N-glycans by adding GlcNAc in the β1,2 linkage to the α1,6-mannose arm of biantennary structures. This activity influences maturation of glycoproteins that govern receptor trafficking, cell–cell adhesion, and growth factor signaling, thereby shaping membrane proteostasis and extracellular interactions. Altered MGAT2-dependent N-glycan branching and composition has been associated with dysregulated cellular signaling and changes in migration and invasiveness in cancer-relevant contexts, and is also linked to congenital disorders of glycosylation involving impaired Golgi processing. As a result, MGAT2 is frequently studied in glycoproteomics, secretory pathway biology, and pathway-level analyses of N-glycan remodeling.
GnT-II CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MGAT2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MGAT2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MGAT2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GnT-II protein expression.
This CRISPR knockout system enables efficient generation of MGAT2-deficient cell models for investigation of GnT-II signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MGAT2 exon(s) critical for GnT-II function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MGAT2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GnT-II CRISPR/Cas9 KO Plasmid (h) and GnT-II CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MGAT2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GnT-II HDR Plasmid (h) and GnT-II HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MGAT2 homology arms to support homology-directed repair at defined MGAT2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.